Join to view full profile
800 Howard AvenueYale Physicians BuildingNew Haven, CT 06519
Dr. Leapman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Minimally Invasive Urologic Surgery, 2014 - 2016
Icahn School of Medicine at Mount SinaiResidency, Urology, 2010 - 2014- Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 2009 - 2010
University of Maryland School of MedicineClass of 2009
Certifications & Licensure
CT State Medical License 2016 - 2027
NY State Medical License 2011 - 2015
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Publications & Presentations
PubMed
- Mirror worlds: The shared regulatory architecture of cell fate in development and cancer.Melanie Fraidenburg, Longjun Li, Rosa Kwon, Fady Ghali, Joshua Warrick
Cancer Letters. 2026-10-28 - Comparison and interpretability of machine learning algorithms to predict survival of patients with prostate cancer.Isaac E Kim, Cecile P G Meier-Scherling, Steve R Zhou, Simon J C Soerensen, Ismail Ajjawi
Urologic Oncology. 2026-10-01 - Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.Aaron P Mitchell, Andrew Salner, Paul Palyca, Azeez Farooki, Sonia Persaud
JCO Oncology Practice. 2026-09-01
Journal Articles
- Regional Adoption of Commercial Gene Expression Testing for Prostate CancerMichael Leapman, MD, JAMA Oncology
Authored Content
- The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-AnalysisApril 2021
Press Mentions
Community Collaboration Supports Prostate Cancer Rally in New HavenJanuary 5th, 2026- “Declines in Opioid Prescribing for Cancer PatientsSeptember 23rd, 2025
- New Research Examines Racial Disparities in Prostate Cancer CareJuly 29th, 2025
Grant Support
- Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imagingYALE UNIVERSITY2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: